Cargando…
One-Year estimated GFR Slope Independently Predicts Clinical Benefit in Immunoglobulin A Nephropathy
Autores principales: | Lafayette, Richard A., Reich, Heather N., Stone, Andrew M., Barratt, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727523/ https://www.ncbi.nlm.nih.gov/pubmed/36506237 http://dx.doi.org/10.1016/j.ekir.2022.09.017 |
Ejemplares similares
-
International Physicians Delphi Survey: Managing Patients With IgA Nephropathy
por: Floege, Jürgen, et al.
Publicado: (2022) -
Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy
por: Lafayette, Richard A., et al.
Publicado: (2020) -
Association of glomerular DNA damage and DNA methylation with one-year eGFR decline in IgA nephropathy
por: Hayashi, Kaori, et al.
Publicado: (2020) -
Renal Function Trajectories in Patients with Prior Improved eGFR Slopes and Risk of Death
por: Xie, Yan, et al.
Publicado: (2016) -
Reduced cystatin C-estimated GFR and increased creatinine-estimated GFR in comparison with iohexol-estimated GFR in a hyperthyroid patient: A case report
por: Karawajczyk, Malgorzata, et al.
Publicado: (2008)